Dirk Strumberg

Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors

Dirk Strumberg, Heike Richly, Ralf A. Hilger et al. · Journal of Clinical Oncology · 2004 · 870 citations · Full text

Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial

Michael Untch, Sibylle Loibl, Joachim Bischoff et al. · The Lancet Oncology · 2012 · 453 citations

Gbg 44, Medicine, Randomised Phase 3 +7

Intraperitoneal Chemotherapy of Peritoneal Carcinomatosis Using Pressurized Aerosol as an Alternative to Liquid Solution: First Evidence for Efficacy

Reinhold Kerb, Thomas E. Mürdter, Urs Giger-Pabst et al. · Annals of Surgical Oncology · 2013 · 364 citations · Full text

Conversion of Topoisomerase I Cleavage Complexes on the Leading Strand of Ribosomal DNA into 5′-Phosphorylated DNA Double-Strand Breaks by Replication Runoff

Dirk Strumberg, André A. Pilon, Melanie Smith et al. · Molecular and Cellular Biology · 2000 · 354 citations · Full text

Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours

Ahmad Awada, Alain Hendlisz, Thierry Gil et al. · British Journal of Cancer · 2005 · 338 citations · Full text